CAS 1405-10-3|Neomycin sulfate

Introduction：Basic information about CAS 1405-10-3|Neomycin sulfate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Neomycin sulfate BiologicalActivity
3. Chemical & Physical Properties
4. Toxicological Information
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
5. Safety Information
6. Customs
7. Articles48
8. Synonyms

Common Name	Neomycin sulfate
CAS Number	1405-10-3	Molecular Weight	908.88
Density	/	Boiling Point	1046.1ºC at 760 mmHg
Molecular Formula	C₂₃H₅₂N₆O₂₅S₃	Melting Point	>187°C (dec.)
MSDS	ChineseUSA	Flash Point	586.5ºC
Symbol	GHS08	Signal Word	Danger

Names

Name	Fradiomycin Sulfate
Synonym	More Synonyms

Neomycin sulfate BiologicalActivity

Description	Neomycin sulfate is an aminoglycoside antibiotic used for preventing or treating bacterial infections.
Related Catalog	Signaling Pathways >>Anti-infection >>BacterialSignaling Pathways >>Membrane Transporter/Ion Channel >>Calcium ChannelResearch Areas >>Infection
In Vitro	Neomycin inhibits thrombin-stimulated release of inositol 1,4,5-trisphosphate (IP3), by selectively binding PIP2, but does not inhibit 32P incorporation into PI or initiation of DNA synthesis[1]. Neomycin (10 μM-1 mM) induces considerable release of [3H]arachidonic acid from phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine in saponin-permeabilized human platelets prelabeled with [3H]arachidonic acid. Moreover, neomycin enhances arachidonic acid release induced by thrombin. Addition of neomycin (100 μM) to 45Ca2+-preloaded platelets elicits 45Ca2+ mobilizatioin from intracellular stores[2]. Neomycin (0-10 mM) inhibits guanosine 5'-[gamma-thio]triphosphate-stimulated PLD activity in digitonin-permeabilized NG108-15 cells in a concentration-dependent manner (50% inhibition at 100 μM). Neomycin similarly inhibits PLD activity present in rat brain membranes and assayed in vitro with [3H]phosphatidylcholine as substrate (50% inhibition at 65 μM)[3]. Neomycin (5 mM) causes reversible reductions in the level of intracellular Ca2+, but PtdIns(4,5)P2 is not required for the channel activity[4].
References	[1]. Carney, D.H., et al. Phosphoinositides in mitogenesis: neomycin inhibits thrombin-stimulated phosphoinositide turnover and initiation of cell proliferation. Cell, 1985. 42(2): p. 479-88. [2]. Nakashima, S., et al. Neomycin is a potent agent for arachidonic acid release in human platelets. Biochem Biophys Res Commun, 1987. 146(2): p. 820-6. [3]. Liscovitch, M., et al., Inhibition of neural phospholipase D activity by aminoglycoside antibiotics. Biochem J, 1991. 279 ( Pt 1): p. 319-21. [4]. Huang K, et al. CRAC channel is inhibited by neomycin in a Ptdlns(4,5)P2-independent manner. Cell Biochem Funct. 2015 Mar;33(2):97-100.

Chemical & Physical Properties

Boiling Point	1046.1ºC at 760 mmHg
Melting Point	>187°C (dec.)
Molecular Formula	C₂₃H₅₂N₆O₂₅S₃
Molecular Weight	908.88
Flash Point	586.5ºC
PSA	436.09000
Vapour Pressure	0mmHg at 25°C
Index of Refraction	56 ° (C=10, H2O)
InChIKey	KWBUARAINLGYMG-BNAHOEIWSA-N
SMILES	NCC1OC(OC2C(CO)OC(OC3C(O)C(N)CC(N)C3OC3OC(CN)C(O)C(O)C3N)C2O)C(N)C(O)C1O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O
Storage condition	2-8°C
Stability	Stable. Incompatible with strong oxidizing agents.
Water Solubility	H2O: 50 mg/mL As a stock solution. Stock solutions should be filter sterilized and stored at 2-8°C. Stable at 37°C for 5 days.

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: QP4375000

CHEMICAL NAME :: Neomycin, sulfate (salt)

CAS REGISTRY NUMBER :: 1405-10-3

LAST UPDATED :: 199701

WISWESSER LINE NOTATION :: T6OTJ CZ DQ EQ F1Z BO- CT5OTJ B1Q DQ EO- CL6TJ AZ BQ EZ DO- BT6OTJ CZ DQ EQ F1Z &WSQQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: Standard Draize test

ROUTE OF EXPOSURE :: Administration onto the skin

SPECIES OBSERVED :: Human

REFERENCE :: 85DKA8 "Cutaneous Toxicity, Proceedings of the 3rd Conference, 1976," Drill, V.A., and P. Lazar, eds., New York, Academic Press, Inc. 1977 Volume(issue)/page/year: -,127,1977 ** ACUTE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 12600 mg/kg/7D

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - hallucinations, distorted perceptions Behavioral - anorexia (human)

REFERENCE :: ARSUAX Archives of Surgery (Chicago). (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1-61, 1920-50; V.81- 1960- Volume(issue)/page/year: 111,822,1976

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 200 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 12,597,1962

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >8 gm(base)/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: AACHAX Antimicrobial Agents and Chemotherapy (1961-70). (Ann Arbor, MI) 1961-70. For publisher information, see AMACCQ. Volume(issue)/page/year: -,138,1963

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 305 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ANTCAO Antibiotics and Chemotherapy (Washington, DC). (Washington, DC) V.1-12, 1951-62. For publisher information, see CLMEA3. Volume(issue)/page/year: 8,198,1958

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 190 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ANTBAL Antibiotiki. (Moscow, USSR) V.1-29, 1956-84. For publisher information, see AMBIEH. Volume(issue)/page/year: 18,444,1973

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 17400 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: AITEAT Archivum Immunologiae et Therapiae Experimentalis. (Ars Polona, POB 1001, 00-068 Warsaw 1, Poland) V.10- 1962- Volume(issue)/page/year: 10,947,1962

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 142 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold

REFERENCE :: AIMDAP Archives of Internal Medicine. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1908- Volume(issue)/page/year: 119,493,1967

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intracerebral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 32 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 7,361,1965

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: >250 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Ear) - change in acuity

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 33,320,1975 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 280 mg/kg/7D-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - changes in bladder weight Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphatases

REFERENCE :: CBPCEE Comparative Biochemistry and Physiology, C: Pharmacology, Toxicology and Endocrinology. (Elsevier Science, 660 White Plains Rd., Tarrytown, NY 10591) V.74- 1983- Volume(issue)/page/year: 109,77,1994

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 560 mg/kg/7D-I

TOXIC EFFECTS :: Gastrointestinal - other changes Kidney, Ureter, Bladder - other changes in urine composition Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - other Enzymes

REFERENCE :: CBPCEE Comparative Biochemistry and Physiology, C: Pharmacology, Toxicology and Endocrinology. (Elsevier Science, 660 White Plains Rd., Tarrytown, NY 10591) V.74- 1983- Volume(issue)/page/year: 109,77,1994

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 2 gm/kg/8D-I

TOXIC EFFECTS :: Sense Organs and Special Senses (Ear) - change in acuity Sense Organs and Special Senses (Ear) - changes in cochlear structure or function Related to Chronic Data - death

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 33,320,1975 *** REVIEWS *** TOXICOLOGY REVIEW PMMDAE Panminerva Medica. (Edizioni Minerva Medica, Casella Postale 491, Turin, Italy) V.1- 1959- Volume(issue)/page/year: 16,9,1974 *** U.S. STANDARDS AND REGULATIONS *** EPA FIFRA 1988 PESTICIDE SUBJECT TO REGISTRATION OR RE-REGISTRATION FEREAC Federal Register. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) V.1- 1936- Volume(issue)/page/year: 54,7740,1989 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3700 No. of Facilities: 3566 (estimated) No. of Industries: 23 No. of Occupations: 33 No. of Employees: 180078 (estimated) No. of Female Employees: 143663 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X9498 No. of Facilities: 1014 (estimated) No. of Industries: 5 No. of Occupations: 11 No. of Employees: 16279 (estimated) No. of Female Employees: 12693 (estimated)

Safety Information

Symbol	GHS08
Signal Word	Danger
Hazard Statements	H317-H334
Precautionary Statements	P261-P280-P342 + P311
Personal Protective Equipment	dust mask type N95 (US);Eyeshields;Faceshields;Gloves
Hazard Codes	Xn
Risk Phrases	R42/43
Safety Phrases	23-36/37-45-22-36-24/25
RIDADR	NONH for all modes of transport
WGK Germany	3
RTECS	QP4375000
HS Code	2941909000

Customs

HS Code	2941909000

Articles48

Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis.

Lancet Infect. Dis. 13(4) , 328-41, (2013)

Many meta-analyses have shown reductions in infection rates and mortality associated with the use of selective digestive decontamination (SDD) or selective oropharyngeal decontamination (SOD) in inten...

Clearance of nasal Staphylococcus aureus colonization with triple antibiotic ointment.

Journal. of. Drugs in. Dermatology. 11(12) , 1490-2, (2012)

The prevalence of Staphylococcus aureus colonization of healthcare workers is reported at 30%, with colonization rates for methicillin-resistant S aureus (MRSA) reported between 2.0% and 8.5% among in...

Acute otitis externa: an update.

Am. Fam. Physician 86(11) , 1055-61, (2012)

Acute otitis externa is a common condition involving inflammation of the ear canal. The acute form is caused primarily by bacterial infection, with Pseudomonas aeruginosa and Staphylococcus aureus the...

Synonyms

Neomycin Sulfate

FradioMycin Sulfate

Neomycin Sulphate

Neomycin trisulfate salt hydrate

EINECS 215-773-1

MFCD00037007

Recommended......